Literature DB >> 3028966

Antibacterial activity of ofloxacin and its mode of action.

K Sato, Y Inoue, T Fujii, H Aoyama, S Mitsuhashi.   

Abstract

The antibacterial activity of ofloxacin against Enterobacteriaceae, Pseudomonas aeruginosa, Haemophilus influenzae, Branhamella catarrhalis, and Neisseria gonorrhoeae was comparable to norfloxacin and enoxacin, and far exceeded the activity of pipemidic acid and nalidixic acid. The activity of ofloxacin was two to eight times less than that of ciprofloxacin. Ofloxacin was more active against Staphylococcus aureus, Staphylococcus epidermidis, Streptococcus pneumoniae, Acinetobacter spp., Legionella spp., and Bacteroides fragilis, than norfloxacin, enoxacin, pipemidic acid and nalidixic acid, and the activity of ofloxacin was comparable to that of ciprofloxacin. Ofloxacin was two to seven times more effective than norfloxacin in systemic infections in mice with S. aureus, Escherichia coli, Serratia marcescens and P. aeruginosa. Ofloxacin strongly inhibited DNA supercoiling activity of DNA gyrase purified from E. coli KL-16. There is a parallel relationship between antibacterial activity of ofloxacin and its inhibitory action against DNA gyrases from ofloxacin-susceptible and ofloxacin-resistant clinical isolates of E. coli. These results indicate that the high bactericidal action of ofloxacin and the related new quinolone agents can be explained by their potent inhibitory activities against DNA gyrase in bacterial cells.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3028966     DOI: 10.1007/BF01661277

Source DB:  PubMed          Journal:  Infection        ISSN: 0300-8126            Impact factor:   3.553


  16 in total

1.  DNA gyrase: purification and catalytic properties of a fragment of gyrase B protein.

Authors:  M Gellert; L M Fisher; M H O'Dea
Journal:  Proc Natl Acad Sci U S A       Date:  1979-12       Impact factor: 11.205

2.  Isolation and characterisation of a strain carrying a conditional lethal mutation in the cou gene of Escherichia coli K12.

Authors:  E Orr; N F Fairweather; I B Holland; R H Pritchard
Journal:  Mol Gen Genet       Date:  1979

Review 3.  Recalibrated linkage map of Escherichia coli K-12.

Authors:  B J Bachmann; K B Low; A L Taylor
Journal:  Bacteriol Rev       Date:  1976-03

4.  Replication of colicin E1 plasmid DNA in cell extracts.

Authors:  Y Sakakibara; J I Tomizawa
Journal:  Proc Natl Acad Sci U S A       Date:  1974-03       Impact factor: 11.205

5.  New nalidixic acid resistance mutations related to deoxyribonucleic acid gyrase activity.

Authors:  J Yamagishi; Y Furutani; S Inoue; T Ohue; S Nakamura; M Shimizu
Journal:  J Bacteriol       Date:  1981-11       Impact factor: 3.490

6.  Escherichia coli K-12 mutants resistant to nalidixic acid: genetic mapping and dominance studies.

Authors:  M W Hane; T H Wood
Journal:  J Bacteriol       Date:  1969-07       Impact factor: 3.490

7.  Lambda transducing phages for the nalA gene of Escherichia coli and conditional lethal nalA mutations.

Authors:  K N Kreuzer; K McEntee; A P Geballe; N R Cozzarelli
Journal:  Mol Gen Genet       Date:  1978-11-29

8.  In vitro and in vivo antibacterial activity of AT-2266.

Authors:  K Kouno; M Inoue; S Mitsuhashi
Journal:  Antimicrob Agents Chemother       Date:  1983-07       Impact factor: 5.191

9.  Comparative activities of ciprofloxacin (Bay o 9867), norfloxacin, pipemidic acid, and nalidixic acid.

Authors:  H L Muytjens; J van der Ros-van de Repe; G van Veldhuizen
Journal:  Antimicrob Agents Chemother       Date:  1983-08       Impact factor: 5.191

10.  DNA gyrase: affinity chromatography on novobiocin-Sepharose and catalytic properties.

Authors:  W L Staudenbauer; E Orr
Journal:  Nucleic Acids Res       Date:  1981-08-11       Impact factor: 16.971

View more
  11 in total

1.  Inhibitory effects of quinolones on DNA gyrase of Escherichia coli and topoisomerase II of fetal calf thymus.

Authors:  K Hoshino; K Sato; T Une; Y Osada
Journal:  Antimicrob Agents Chemother       Date:  1989-10       Impact factor: 5.191

2.  Comparison of ofloxacin, gentamicin, and tobramycin concentrations in tears and in vitro MICs for 90% of test organisms.

Authors:  J Richman; H Zolezio; D Tang-Liu
Journal:  Antimicrob Agents Chemother       Date:  1990-08       Impact factor: 5.191

3.  Comparison of inhibition of Escherichia coli topoisomerase IV by quinolones with DNA gyrase inhibition.

Authors:  K Hoshino; A Kitamura; I Morrissey; K Sato; J Kato; H Ikeda
Journal:  Antimicrob Agents Chemother       Date:  1994-11       Impact factor: 5.191

Review 4.  Ofloxacin clinical pharmacokinetics.

Authors:  K C Lamp; E M Bailey; M J Rybak
Journal:  Clin Pharmacokinet       Date:  1992-01       Impact factor: 6.447

5.  Validation of a Standard Luminescence Method for the Fast Determination of the Antimicrobial Activity of Nanoparticles in Escherichia coli.

Authors:  Gonçalo A Marcelo; Joana Galhano; Maria Paula Duarte; José Luis Capelo-Martínez; Carlos Lodeiro; Elisabete Oliveira
Journal:  Nanomaterials (Basel)       Date:  2022-06-23       Impact factor: 5.719

6.  Ofloxacin compared with chloramphenicol in the management of external ocular infection.

Authors:  A J Bron; G Leber; S N Rizk; H Baig; A R Elkington; G R Kirkby; C Neoh; A Harden; T Leong
Journal:  Br J Ophthalmol       Date:  1991-11       Impact factor: 4.638

7.  Topical ofloxacin compared with gentamicin in the treatment of external ocular infection. Ofloxacin Study Group.

Authors:  A Gwon
Journal:  Br J Ophthalmol       Date:  1992-12       Impact factor: 4.638

8.  Ofloxacin induces cytoplasmic respiration-deficient mutants in yeast Saccharomyces cerevisiae.

Authors:  M Obernauerová; J Subík; L Ebringer
Journal:  Curr Genet       Date:  1992-05       Impact factor: 3.886

9.  Stationary-Phase Persisters to Ofloxacin Sustain DNA Damage and Require Repair Systems Only during Recovery.

Authors:  Katherine G Völzing; Mark P Brynildsen
Journal:  MBio       Date:  2015-09-01       Impact factor: 7.867

10.  Development of Persister-FACSeq: a method to massively parallelize quantification of persister physiology and its heterogeneity.

Authors:  Theresa C Henry; Mark P Brynildsen
Journal:  Sci Rep       Date:  2016-05-04       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.